行情

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

实时行情|Nasdaq Last Sale

1.380
-0.040
-2.82%
盘后: 1.440 +0.06 +4.35% 17:51 12/06 EST
开盘
1.410
昨收
1.420
最高
1.460
最低
1.350
成交量
13.04万
成交额
--
52周最高
10.99
52周最低
1.300
市值
3,322.68万
市盈率(TTM)
-0.1971
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EARS 新闻

  • The future of the US wireless industry in limbo as T-Mobile and Sprint begin battle to win merger approval
  • CNBC.com.5小时前
  • 5 Safe And Cheap Dividend Stocks To Invest (December 2019)
  • Seeking Alpha - Article.1天前
  • Top Holdings Of Dividend ETFs (Part 2: The Top 7 By Sector In November 2019)
  • Seeking Alpha - Article.1天前
  • Comcast: Undervalued After Recent Pullback
  • Seeking Alpha - Article.2天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

EARS 简况

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
展开

Webull提供Auris Medical Holding Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。